Form 4: Capricor Therapeutics CFO Acquires Shares

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, acquired 3,000 shares of common stock on May 18, 2026, at a price of $1.39 per share.

Summary

• Anthony Bergmann, Chief Financial Officer of Capricor Therapeutics, Inc., acquired 3,000 shares of common stock on May 18, 2026.
• The acquisition was made at a price of $1.39 per share.
• Following this transaction, Mr. Bergmann beneficially owns 11,223 shares of common stock directly.
• The acquired shares were part of a stock option that was originally granted on June 2, 2016, and has undergone adjustments due to a reverse stock split and a share repricing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider stock option exercise and acquisition by the CFO, without providing new financial or strategic information.

Positives

• The Chief Financial Officer's acquisition of shares may signal confidence in the company's future prospects.
• The transaction involved the exercise of a stock option, indicating a potential for value realization from previously granted compensation.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future financial performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by Capricor Therapeutics' CFO, are closely watched by investors as they can provide insights into management's perception of the company's valuation and future prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the CFO's purchase as a positive signal of confidence in the company's stock.
• Employees may interpret this transaction as a sign of management's commitment to the company's success.

Key Dates

Keywords

Capricor Therapeutics, Form 4, Insider Transaction, Stock Option, Beneficial Ownership, Anthony Bergmann, CFO